Showing 1 - 10 of 21 Nervous System Diseases & Disorders
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis

Status: Enrolling

Investigator: Sheetal Shroff

Study Coordinator:

Phone:

The purpose of the MycarinGstudy is to demonstrate the clinical efficacy and to assess safety and tolerability of rozanolixizumab in patients with generalized myasthenia gravis (MG). NCT number: NCT03971422 ... Read more >

A prospective, multi-center, observational study of the safety, tolerability and effectiveness of SPINRAZA in adult patients with Spinal Muscular Atr

Status: Enrolling

Investigator: Jason Thonhoff

Study Coordinator:

Phone:

The purpose of this study is to measure the safety and effectiveness of Spinraza in adults with SMA. ... Read more >

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy (NCT03149003)

Status: Enrolling

Investigator: David Baskin

Study Coordinator: Larisse Yewah Gwei

Phone: 713.441.3834

This is a randomized, active-controlled, multicenter, open-label, parallel groups, Phase 2 study of DSP-7888 Dosing Emulsion plus Bevacizumab versus Bevacizumab alone in patients with recurrent or progressive glioblastoma multiforme (GBM) follow ... Read more >

A Randomized, Open-Label Extension Study to Investigate the Long-Term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis

Status: Enrolling

Investigator: Sheetal Shroff

Study Coordinator:

Phone:

The purpose of the MycarinGstudy is to evaluate the long-term safety, tolerability and long-term efficacy of rozanolixizumab in study participants with generalized myasthenia gravis (MG). NCT number: NCT04124965 ... Read more >

A Randomized, Placebo-control, Parallel Group Study to Evaluate the Effect of Amifampridine Phosphate in Patients With MuSK Antibody Positive Myasthenia Gravis, and a Sample of AChR Antibody Positive Myasthenia Gravis Patients

Status: Enrolling

Investigator: Ericka Greene

Study Coordinator: Sharon Halton

Phone: 713.441.3420

Efficacy and safety of amifampridine phosphate in improving the activities of daily living for patients with antibody positive MuSK myasthenia gravis. NCT Number:NCT03304054 ... Read more >

An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS)-VALOR

Status: Enrolling

Investigator: Ericka Greene

Study Coordinator: Rachel Applegate

Phone: 713.441.9120

This study is only eligible for ALS patients who are positive for the SOD1 gene. It is a double blind, placebo controlled infusion of an antisense oligonucleotide, administered intrathecally 8 times over the course of the 28 week study. There is ... Read more >

An Open-Label, Expanded Access Protocol for Amifampridine Phosphate Treatment in Patients With Congenital Myasthenic Syndrome (CMS)

Status: Enrolling

Investigator: Sheetal Shroff

Study Coordinator:

Phone:

The primary objective of the study is: • To provide patients with CMS access to amifampridine phosphate therapy until the product becomes commercially available or development is discontinued. The secondary objective of the study is: • ... Read more >

ATLAS

Status: Open Not Enrolling

Investigator: Richard Klucznik

Study Coordinator: Sergio Ibarra Cortez

Phone: 956.543.5198

.The primary objective of this study is to demonstrate effectiveness and safety of the NeuroForm Atlas stent system for use with bare metal embolic coils ... Read more >

COMPILATIONS OF CLINICAL FINDINGS IN AMYOTROPHIC LATERAL SCLEROSIS

Status: Open Not Enrolling

Investigator: Stanley Appel

Study Coordinator:

Phone:

The purpose of this protocol is to develop and maintain a clinical findings data bank including diagnostic evaluations obtained from medical records sent from prior medical evaluations, diagnostic intake evaluations and follow-up care in the Met ... Read more >

CREST-2

Status: Enrolling

Investigator: David Chiu

Study Coordinator: Jason Lee

Phone: 713.394.6479

Carotid revascularization for primary prevention of stroke (CREST-2) is two independent multicenter, randomized controlled trials of carotid revascularization and intensive medical management versus medical management alone in patients with asym ... Read more >

Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1: END-DM1

Status: Enrolling

Investigator: Ericka Greene

Study Coordinator: Sharon Halton

Phone: 713.441.3420

Provide natural history data, biomarkers, and biological understanding of the phenotypic heterogeneity of myotonic dystrophy type 1 (DM1). ... Read more >

Genomic Translation for ALS Clinical Care

Status: Enrolling

Investigator: Stanley Appel

Study Coordinator: Sharon Halton

Phone: 713.441.3420

The purpose of the this study to look for abnormal genes and gene expression profiles that help determine why a person develops amyotrophic lateral sclerosis (ALS) and related motor neuron diseases (MND) and why their symptoms present and progre ... Read more >

Long Term Safety Study of Amifampridine Phosphate in Patients With MuSK Antibody Positive and AChR (Acetylcholine Receptor) Antibody Positive Myasthenia Gravis

Status: Enrolling

Investigator: Ericka Greene

Study Coordinator: Sharon Halton

Phone: 713.441.3420

Evaluate the long-term safety of amifampridine phosphate in the symptomatic relief of antibody positive MuSK-MG. NCT Number: NCT03579966 ... Read more >

Myotonic Dystrophy Compilation of Clinical Findings

Status: Open Not Enrolling

Investigator: Ericka Greene

Study Coordinator: Sharon Halton

Phone: 713.441.3420

The purpose of this protocol is to make available clinical findings, including blood pressure, pulmonary function tests, cardiac function tests, clinical evaluations, cognitive evaluations, performance tests, medications, routine blood work eval ... Read more >

Neuromuscular Observational Research (MOVR) Data Hub Protocol

Status: Enrolling

Investigator: Ericka Greene

Study Coordinator:

Phone:

This is a registry of people with neuromuscular diseases. It is the intent to follow patients with ALS and other neuromuscular diseases to determine best practices for care delivery. ... Read more >

NWBT 020221 - DC-Vax

Status: Open Not Enrolling

Investigator: David Baskin

Study Coordinator: Helga Jones

Phone: 713.363.9388

" Purpose The primary purpose of the study is to determine the efficacy of an investigational therapy called DCVax(R)-L in patients with newly diagnosed GBM for whom surgery is indicated. Patients must enter screening at a participating site p ... Read more >

Phase III Efficacy, Safety, and Tolerability Study of HYQVIA/HyQvia and GAMMAGARD LIQUID/KIOVIG in CIDP

Status: Enrolling

Investigator: Ericka Greene

Study Coordinator: Sharon Halton

Phone: 713.441.3420

This is a Phase III, prospective, multicenter study with two study parts (epochs) to evaluate the efficacy, safety, and tolerability of HYQVIA/HyQvia (IGI, 10% with recombinant human hyaluronidase (rHuPH20) administered subcutaneously) for maint ... Read more >

Phase I-II Study Evaluating HSV-tk + Valacyclovir Gene Therapy

Status: Open Not Enrolling

Investigator: David Baskin

Study Coordinator: Larisse Yewah Gwei

Phone: 713.441.3834

NCT03603405 This is a prospective, phase I-II study to assess the efficacy and toxicity of HSV-tk + valacyclovir gene therapy in combination with radiotherapy and standard of care chemotherapy for anaplastic astrocytoma (AA) or glioblastoma mul ... Read more >

Phase I-II Study Evaluating HSV-tk + Valacyclovir Gene Therapy Combination with Radiotherapy and Chemotherapy for Recurrent Glioblastoma Multiforme

Status: Open Not Enrolling

Investigator: David Baskin

Study Coordinator: Larisse Yewah Gwei

Phone: 713.441.3834

NCT03596086 This is a prospective phase I-II study to assess the efficacy and toxicity of HSV-tk + valacyclovir gene therapy in combination with radiotherapy and standard of care chemotherapy in recurrent anaplastic astrocytoma or glioblastoma ... Read more >

Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis

Status: Enrolling

Investigator: Ericka Greene

Study Coordinator: Sharon Halton

Phone: 713.441.3420

The primary purpose of this study is to evaluate the safety and efficacy of ravulizumab for the treatment of participants with generalized myasthenia gravis (gMG). [NCT03920293] ... Read more >

T-regulatory Cells in ALS (Tregs in ALS)

Status: Active

Investigator: Jason Thonhoff

Study Coordinator: Patricia Mendoza

Phone: 713.441.5855

This study is a randomized, placebo-controlled, phase 2a trial to study the biological activity, safety, and tolerability of regulatory T Lymphocytes (Tregs) taken and expanded outside of the body and returned back to the same person whose Treg ... Read more >

Live Chat Available